Medis Group

What Medis Group does

Medis Group (Les Laboratoires MédiS) is a Tunisian privately-held pharmaceutical company founded in 1995, headquartered in Nabeul with an Operations Department in Tunis. It manufactures and commercializes generic pharmaceutical products across 17 therapeutic domains — including anesthesiology, cardiology, gastroenterology, hematology, infectiology, metabolism and nutrition, neurology, oncology, ophthalmology, psychiatry, radiology, rheumatology, and urology-nephrology — under brands such as IPProton (omeprazole), Glargen (insulin glargine), VAINCOR (olanzapine), VANCO (vancomycin), REMIFENTANIL MEDIS, APIXADIS (apixaban), VIADIS (sildenafil), DIABIPHAGE (metformin), and the VITAWIN dietary supplement range. The portfolio exceeds 1,200 products and is produced at GMP-certified manufacturing facilities in Nabeul, with an oncology-focused subsidiary (Neapolis Pharma) addressing domestic anticancer drug demand and regional operating subsidiaries in Algeria (inphamédis) and Senegal (Medis Senegal, acquired from Sanofi in 2017).

The company serves healthcare providers, retail and hospital pharmacies, and government health institutions, distributing products through a direct medical-representative sales force domestically and through regional channel partners (e.g., Salehiya Trading in Saudi Arabia) internationally, reaching 38 countries across Africa, Europe, and the Middle East. Its go-to-market is sales-led with quote-based B2B/B2G pricing and no public price list; revenue is generated through one-time product sales rather than subscriptions or licensing. Marketing is multi-channel, combining scientific publications, health podcasts, health-capsule video content, medical-congress participation (e.g., SOTCOT with Prix MédiS), and active social-media presence aimed at healthcare professionals and patients.

Medis is led by General Director Lassaad Boujbel (also designated as founder & CEO) with a senior team including Imen Boujbel (CCO/Group Operations Director), Hatem Amira (Export Director), Haithem Aissa (Global Marketing Director), Issam Zgoli (Digital Marketing Director), Sofiene Bessi (Administrative and Financial Manager), and Sonia Hfeidh (Medical Director). The company was recognized as Tunisia's Best Pharmaceutical Export Company by CEPEX in 2023 and is positioning, around its 30-year anniversary in 2026, as a major player in the regional pharmaceutical industry. Capital structure is a Société Anonyme with 56,000,000 TND in share capital, and the company is privately held with no institutional or public shareholders disclosed.

Name

Medis Group

Legal name

Les Laboratoires MédiS

Website

https://medis.com.tn

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

251–500 employees

Short description

Medis Group is a Tunisian generic pharmaceutical manufacturer founded in 1995, producing 1,200+ products across 17 therapeutic areas. It serves healthcare providers, pharmacies, and government health institutions across Tunisia and 38 export markets spanning Africa, Europe, and the Middle East.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Generic Tender & Government Supply Markets (HLAIABAM), Specialty Care Pharmaceuticals (HLAIAAAB), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Generic pharmaceuticals
• Drug manufacturing
• Therapeutic medications
• Oncology treatments
• Pharmaceutical export

Headquarters

HQ city

Nabeul

HQ country

Tunisia

HQ region

Africa

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: MédiS generates revenue through the manufacture and sale of generic pharmaceutical products across 17 therapeutic domains and 1200+ products. Revenue comes from domestic Tunisian market sales and export to 38 countries across Africa, Europe, and the Middle East. The company operates B2B with healthcare providers, pharmacies, hospitals, and B2G with public health institutions.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Medis Group manufactures and sells a portfolio of more than 1,200 generic pharmaceutical products across 17 therapeutic areas from its GMP-certified facility in Nabeul, Tunisia. The company supplies hospitals, clinics, pharmacies, and public-sector health programs domestically and exports to 38 countries across Africa, Europe, the Middle East, and parts of Asia, with an oncology-dedicated subsidiary (Neapolis Pharma) and a dietary supplement line (VITAWIN range, including the 2025-launched EXTRA COLLAGÈNE).

Product overview

Medis Group is a Tunisian pharmaceutical company founded in 1995, operating as a pharmaceutical laboratory with a broad portfolio of generic medications across 17+ therapeutic areas. The company produces and commercializes pharmaceutical products including cardiovascular medications (AMLODIPINE, ATOR, LOSAR, PIDOGREL), gastrointestinal treatments (IPProton/Omeprazole, ESORAL/Esomeprazole), diabetes medications (Glargen/Insulin, DIABIPHAGE/Metformin, IRYS/Glimepiride), antibiotics (VANCO/Vancomycin, CIPRO/Ciprofloxacin, TEICO/Teicoplanin), psychiatric medications (VAINCOR/Olanzapine, MEDIPREX/Escitalopram, SERVAL/Sertraline), anesthesiology products (REMIFENTANIL, FENTANYL, MEDICAINE), hematology medications (ENOXA/Enoxaparin, EPOMAX/Erythropoietin), and dietary supplements (VITAWIN range, EXTRA COLLAGÈNE). The company operates through subsidiaries including Neapolis Pharma (oncology) and has presence across 38 countries in Africa, Europe, and the Middle East.

Differentiator

Problem solved

Functional benefit

Brands

• VITAWIN: Multivitamin dietary supplement product line including VITAWIN ADULTE, VITAWIN GROSSESSE, VITAWIN JUNIOR, VITAWIN MEMO, VITAWIN ADULTE PLUS
• Neapolis Pharma

Products and services

• Neapolis Pharma (Oncology Subsidiary) Oncology-focused subsidiary providing therapeutic solutions in cancer treatment, reducing domestic reliance on imported anticancer medications.
• IPProton (Omeprazole) Proton pump inhibitor (PPI) for the treatment of digestive pathologies such as gastric reflux and peptic ulcers; the product marked 20 years of innovation and leadership for MédiS.
• ESORAL (Esomeprazole) Proton pump inhibitor for gastrointestinal disorders, available in 20mg and 40mg doses.
• Glargen (Insulin Glargine) Long-acting insulin formulation for diabetes management, available in 3 ml vials for subcutaneous injection.
• DIABIPHAGE (Metformin) Biguanide antidiabetic medication for management of type 2 diabetes, available in 850 mg and 1000 mg doses.
• IRYS (Glimepiride) Sulfonylurea antidiabetic medication for type 2 diabetes treatment, available in 1 mg, 2 mg, 3 mg, 4 mg, and 6 mg doses.
• VIADIS (Sildenafil) Phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction in adult men, available in 25 mg, 50 mg, and 100 mg doses.
• ZOLEDRA / ZOTIMOS (Zoledronic Acid) Bisphosphonate for prevention of bone complications in patients with advanced malignant disease and treatment of tumor-induced hypercalcemia.
• VANCO (Vancomycin) Intravenous glycopeptide antibiotic for treatment of complicated skin infections, bone/joint infections, pneumonia, and infective endocarditis.
• ENOXA / FLUMAX (Enoxaparin) Low molecular weight heparin (LMWH) anticoagulant for prevention of venous thromboembolism and treatment of thromboembolic disorders.
• APIXADIS (Apixaban) Direct oral anticoagulant (Factor Xa inhibitor) for prevention and treatment of blood clots, including stroke prevention in atrial fibrillation and VTE; available in 2.5 mg and 5 mg doses.
• REMIFENTANIL MEDIS Ultra-short acting opioid analgesic for intravenous use during general anesthesia and procedural sedation, available in 1 mg and 5 mg vials.
• VAINCOR (Olanzapine) Atypical antipsychotic for treatment of schizophrenia, manic episodes, and prevention of bipolar disorder recurrences.
• VITAWIN Range Multivitamin and micronutrient dietary supplement line including VITAWIN ADULTE, VITAWIN ADULTE PLUS, VITAWIN GROSSESSE, VITAWIN JUNIOR, and VITAWIN MEMO targeting adult, pregnancy, pediatric, and memory/cognition segments.
• EXTRA COLLAGÈNE Collagen-based dietary supplement marketed for skin beauty and skin health support within the dietary supplements therapeutic area.
• Les Laboratoires MédiS (Founding Generic Pharmaceutical Portfolio) Founding portfolio of generic medications across cardiovascular (AMLODIPINE, ATOR, LOSAR, PIDOGREL), antalgesics (TRAMADIS, STOPALGIC), antibiotics (CIPRO, TEICO), psychiatry (MEDIPREX/Escitalopram, SERVAL/Sertraline), and broader therapeutics built since 1995.

Quantifiable outcome

• Leader in Tunisian generic drug market with strong international growth trajectory

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered core, major and regional.

• Neapolis PharmacoreStrategic or Co-development Partner · 14 April 2017Neapolis Pharma is a subsidiary focused on oncology treatments, established to address Tunisia's need for domestic cancer medication production. The subsidiary was created to reduce reliance on imported anticancer medications which cost over 150 million TND annually.
• SanofimajorStrategic or Co-development Partner · 14 April 2017Sanofi sold its stake in WPS (WinthropPharma Senegal) to MédiS Group, marking MédiS's entry into the Senegalese market and Sub-Saharan Africa. Following Algeria and Czech Republic expansions, this marked a third international market entry.
• inphamédiscoreStrategic or Co-development PartnerSubsidiary operating in Algeria, representing one of MédiS's international expansion markets beyond Tunisia.
• Medis SenegalcoreStrategic or Co-development PartnerSubsidiary established in Senegal through acquisition from Sanofi in 2017, enabling MédiS operations in Sub-Saharan Africa.
• Salehiya Trading CompanyregionalChannel Partner/ Reseller/ DistributorLocal partner in Saudi Arabia responsible for pharmacovigilance activities and market presence. Contacts include Salman Al-Murdhi (QPPV) and Mohammed Waqas (Deputy QPPV).

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Gulf Pharmaceutical Industries (Julphar): UAE-based generic and specialty pharmaceutical manufacturer with MENA-wide distribution and manufacturing in multiple therapeutic areas. Comparable generic-pharma manufacturer competing in the same regional institutional channels as Medis.
• Eva Pharma: Egyptian generic pharmaceutical manufacturer with broad therapeutic-area coverage and significant Africa/MENA export presence. Closely comparable in product breadth, generic focus, and emerging-market commercial model.
• Hikma Pharmaceuticals: Jordan-headquartered multinational generic and specialty pharmaceutical manufacturer with broad MENA, Europe, and US footprint. Most directly comparable to Medis on generic pharma manufacturing for institutional buyers across the same emerging-market geographies.
• Aspen Pharmacare: South African-headquartered generic and specialty pharma group with extensive Sub-Saharan African footprint. Comparable as a leading African-focused generic manufacturer with established institutional and government channels.

Broad incumbents

• Aurobindo Pharma: Indian generic pharmaceutical manufacturer with large global export footprint including Africa and emerging markets. Comparable as a high-volume generic exporter competing for the same institutional and tender business as Medis.
• Cipla: Indian-headquartered global generic pharmaceutical major with strong presence in Africa and emerging markets, including respiratory, antiretroviral, and chronic disease portfolios. Comparable as a scaled generic manufacturer with overlapping emerging-market channels.
• Sanofi: Global pharmaceutical major that previously held Medis Senegal (WPS) and divested to Medis in 2017. Comparable in therapeutic-area breadth, though Sanofi operates at vastly larger scale across branded, specialty, and consumer health.

Regional players

• EIPICO: Egyptian generic pharmaceutical manufacturer serving MENA and select African markets with broad portfolio across multiple therapeutic areas. Comparable generic manufacturing peer within the North African pharma ecosystem.
• Adcock Ingram: South African pharmaceutical manufacturer and distributor serving Sub-Saharan Africa with prescription, OTC, and generic portfolios. Comparable in regional generic pharma manufacturing and African institutional distribution.

Emerging players

• Strides Pharma: Indian-headquartered generic pharmaceutical manufacturer with focus on regulated and emerging markets, including Africa. Comparable as a generic manufacturer with active emerging-market expansion strategy and complex-generic capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@medispharmaceuticals1028
• Facebookfacebook.com/medis.com.tn
• LinkedInlinkedin.com/company/laboratoire-m-dis
• Instagraminstagram.com/labomedis

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medis Group